Global Health Priority Box—Proactive Pandemic Preparedness
Author Information
Author(s): Adam Anna, Besson Dominique, Bryant Rob, Rees Sarah, Willis Paul A., Burrows Jeremy N., Hooft van Huisjduijnen Rob, Laleu Benoît, Norton Larry, Canan Stacie, Hawryluk Natalie, Robinson Dale, Palmer Mike, Samby Kirandeep Kaur
Primary Institution: MMV Medicines for Malaria Venture
Hypothesis
The study addresses the urgent need for new drugs to combat drug-resistant malaria and emerging zoonotic diseases.
Conclusion
The Global Health Priority Box provides a valuable resource for researchers to expedite the development of treatments and insecticides for infectious diseases.
Supporting Evidence
- The Global Health Priority Box was launched in August 2022 to address the urgent need for new drugs.
- Over 120 researchers have requested the GHPB, indicating significant interest in screening high-quality compound collections.
- The GHPB includes compounds targeting drug-resistant malaria and neglected tropical diseases.
Takeaway
This study created a special box of 240 compounds to help scientists find new medicines for diseases like malaria and other infections.
Methodology
The Global Health Priority Box was developed through collaboration between Medicines for Malaria Venture and the Innovative Vector Control Consortium, including a collection of compounds targeting various infectious diseases.
Limitations
The study notes that many drug candidates may fail in clinical development due to various risks, including inadequate efficacy and safety concerns.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website